Pfizer formally asked U.S. regulators Friday to allow emergency use of its COVID-19 vaccine, starting the clock on a process that could bring limited first shots as early as next month and eventually an end to the pandemic -- but not until after a long, hard winter.
BARCELONA/ROME (Reuters) - Thirty-year-old Pep Iglesies emigrated to Canada from Spain in August for a new job that is much like his old one – taking care of coronavirus patients and working as a cardiologist.
(Reuters) - AstraZeneca and Oxford University’s potential COVID-19 vaccine produced a strong immune response in older adults, data published on Thursday showed, with researchers expecting to release late-stage trial results by Christmas.
The promising news that not just one but two coronavirus vaccines were more than 90 percent effective in early results has buoyed hopes that an end to the pandemic is in sight.
But even if the vaccines are authorized soon by federal regulators — the companies developing them have said they expect to apply soon — only a sliver of the American public will be able to get one by the end of the year. The two companies, Pfizer and Moderna, have estimated they will have 45 million doses, or enough to vaccinate 22.5 million Americans, by January.
WASHINGTON (AP) — U.S. regulators on Tuesday allowed emergency use of the first rapid coronavirus test that can be performed entirely at home and delivers results in 30 minutes.
Recent Comments